Pharmaceutical formulations and methods for the topical and/or transdermal
delivery of imiquimod, including creams, ointments and pressure-sensitive
adhesive compositions to treat dermatological disorders, namely, viral
infections, such as Type I or Type II Herpes simplex infections and
genital warts, actinic keratosis and superficial basal cell carcinoma,
and to induce interferon biosynthesis, with shorter durations of therapy,
than currently approved for imiquimod by the Food & Drug Administration
("FDA").